What is Cryoport Inc?
provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide.
CYRX · Verdict
Moderate reward · elevated risk
CYRX has limited near-term tailwinds — profitability and volatility weigh on the model output.
Based on 88% data coverage
CYRX · Verdict
-43% net margin · -11% ROE
Weak vs peers
-14% free-cash-flow margin
Current ratio 5.29
Rev +1.6% CAGR · earnings -28.8%
Model-based scoring. For information only — not financial advice.
provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company's Life Sciences Services segment provides temperature-controlled logistics and cryogenic biostorage within the life science industry. The company is listed on the NASDAQ in USA, operating in the Industrials sector, with a market capitalisation of 414.07M.
The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.
For informational purposes only. Not financial advice.